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Background: Tobacco burdens in India and Pakistan require continued efforts to quantify tobacco use and its
impacts. We examined the prevalence and sociodemographic and health-related correlates of tobacco use in Delhi,
Chennai (India), and Karachi (Pakistan).
Methods: Analysis of representative surveys of 11,260 participants (selected through multistage cluster random
sampling; stratified by gender and age) in 2011 measured socio-demographics, tobacco use history, comorbid
health conditions, and salivary cotinine. We used bivariate and multivariate regression analyses to examine factors
associated with tobacco use.
Results: Overall, 51.8 % were females, and 61.6 % were below the age of 45 years. Lifetime (ever) tobacco use
prevalence (standardized for world population) was 45.0 %, 41.3 %, and 42.5 % among males, and 7.6 %, 8.5 %,
and 19.7 % among females in Chennai, Delhi, and Karachi, respectively. Past 6 month tobacco use prevalence
(standardized for world population) was 38.6 %, 36.1 %, and 39.1 % among males, and 7.3 %, 7.1 %, and 18.6 %
among females in Chennai, Delhi, and Karachi, respectively. In multivariable regression analyses, residing in Delhi
or Karachi versus Chennai; older age; lower education; earning less income; lower BMI; were each associated with
tobacco use in both sexes. In addition, semi-skilled occupation versus not working and alcohol use were associated
with tobacco use in males, and having newly diagnosed dyslipidemia was associated with lower odds of tobacco use
among females. Mean salivary cotinine levels were higher among tobacco users versus nonusers (235.4; CI: 187.0-283.8
vs. 29.7; CI: 4.2, 55.2, respectively).
Conclusion: High prevalence of tobacco use in the South Asian region, particularly among men, highlights the
urgency to address this serious public health problem. Our analyses suggest targeted prevention and cessation
interventions focused on lower socioeconomic groups may be particularly important.
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Tobacco use surveillance is critical, given that tobacco
use, particularly cigarette smoking, is the leading pre-
ventable cause of mortality around the world [1]. It
responsible for over 5 million deaths per year-more than
HIV/AIDS, tuberculosis, and malaria combined [1,2].
Smoking increases the risk of cardiovascular disease
(CVD) by 2 to 4 times, stroke by 2 to 4 times, and dia-
betes mellitus by 30-40 % [1]. In addition, smoking inter-
acts with other CVD risk factors, such as hypertension
and dyslipdemia, in increasing long-term CVD mortality
[3–6]. Moreover, smoking causes diminished overall
heath, including self-reported poor health, increased
absenteeism from work, and increased health care
utilization and cost [4].
Between 1980 and 2012, the global estimated age-
standardized prevalence of daily tobacco smoking de-
clined by 25 % for men and by 42 % for women;
however, the population growth during this time con-
tributed to a 41 % increase in male daily smokers and a
7 % increase for female smokers [7]. Moreover, over this
period, cigarette consumption worldwide increased by
26 %, indicating continued growth of the global tobacco
market [7]. According to the World Health Organization
[WHO], if appropriate preventive measures are not
taken, the number of annual deaths will increase to 10
million per year by 2030, with 70 % of them taking place
in low-and middle-income countries [8]. Thus, conti-
nued efforts are needed to provide up-to-date estimates
of tobacco use, including the broad range of tobacco
products. Documenting correlates of use as well as the
impact of these products on tobacco-related health con-
ditions is critical for curbing the tobacco use pandemic
and the related chronic health conditions, as it will help
elucidate vulnerable populations and potential interven-
tion targets.
A recent analysis of tobacco use data from nine coun-
tries in South and Southeast Asia found high prevalence
of tobacco use in this region, ranging from 72 % in
Indonesia to 32 % in Pakistan (with India’s prevalence
being 34 %) [9]. This study also documented the use of
tobacco in very diverse forms, particularly in India.
Another study in India from 2009 to 2011 [10] found an
overall tobacco use prevalence of 21 %, with 40 % of
males being tobacco users compared to 5 % of females.
A 2013 study in Pakistan [11] documented a current to-
bacco use prevalence (weighted to correspond to rural-
urban population proportions in the sample) of 45 %
among males and 6 % among females. In both India and
Pakistan, some predictors of tobacco use include older
age, male gender, low socioeconomic status, alcohol use,
and rural geographic location [10,12,13]. This high pre-
valence is concerning given that South Asians have an
increased risk of tobacco-related diseases, such as CVDand other CVD risk factors (e.g., diabetes, hypertension,
and dyslipidemia) [14–17].
Given the public health importance, it is critical to
track tobacco use within specific contexts in South Asia
and characterize tobacco use patterns in terms of popu-
lations vulnerable to tobacco use and the types of to-
bacco being used. In this manuscript, we report the
prevalence of tobacco use and its correlates among males
and females in three specific cities in South Asia – Delhi,
Chennai, and Karachi – using data from the Center for
Cardio-metabolic Risk Reduction in South Asia (CARRS)
Study. CARRS collects data regarding determinants (e.g.,
lifestyle factors) and occurrence of cardio-metabolic dis-
eases; patient-reported quality of life; and costs using stan-
dardized tools and methods from representative samples
in these three cities.Methods
Study design
This study was approved by the Independent Ethics
Committees of Public Health Foundation of India, All
India Institute of Medical Sciences, Madras Diabetes
Research Foundation and Aga Khan University, and Emory
University’s Institutional Review Board. The CARRS Study
[18] builds on the WHO STEPS model [19] to cap-
ture prevalence of risk factors, cardio-metabolic diseases
(CMDs), and their socioeconomic impact. The study sites
for the CARRS Study were metropolitan urban settings
with large, heterogeneous populations (Chennai, popula-
tion 4.68 million [20], Delhi, population 16.8 million [20],
and Karachi, population 13 million [21]) that are growing
due to continued births and migration from various parts
of the country. The CARRS cohort study includes repre-
sentative cross-sectional surveys of these three cities in
South Asia as its baseline, conducted between October
2010 and December 2011 (see [18] for detailed methods).Participants
Households were selected in each of the three cities
using multi-stage cluster random sampling techniques.
Each city has its own distinctive municipal sub-divisions,
encompassing municipal corporations, wards, and Census
Enumeration Blocks (CEB), which were used sequentially
as sampling frames to randomly select households. While
wards were the primary sampling units (PSUs) for Chennai
and Delhi, CEBs or clusters were the PSUs for Karachi.
STATA version 10.1 (Statacorp, TX) and data from the
most recent census (2001) were used to randomly select
the wards, CEBs, and households. To give each household
an equal chance of being selected for the study and to
identify households constructed after the last census sur-
vey, manual listing and mapping of all households in each
CEB was done before randomly selecting them.
Berg et al. BMC Public Health  (2015) 15:483 Page 3 of 12Two participants, one male and one female, aged
20 years or older, were selected from each household.
Those excluded from the study were pregnant women
and bed-ridden individuals. Two methods were used for
within household sampling. First, for households with
one to two adults (≥20 years), the sampling strategy de-
scribed in the 2002 Health Information National Trends
Study (HINTS) in the USA was used [22]. According to
HINTS, one or both individuals (one male, one female)
were selected and enrolled into the study based on eligi-
bility criteria and informed consent. Second, for house-
holds with more than two eligible adults, the “Kish
method” used in the WHO’s STEPS surveys [23] was
applied. There are two main steps in KISH method.
First, all eligible participants from the household will be
ranked according to age in decreasing orders (males
followed by females). Participants are then selected using
KISH table identifying the last digit of household and
number of eligible participants [23]. Recruitment of par-
ticipants and data collection were conducted through
three visits to each participant’s place of residence, re-
spectively. The sample size estimation, specifics on data
collection, data management efforts, and quality control
strategies have been published separately [18].
Measures
For the current analyses, we included the variables listed
below.
Correlates of tobacco Use
Sociodemographic Factors. Participants were asked to re-
port age; gender; education level (up to primary, high/
secondary, graduate, above graduation); occupation (not
working, professional [e.g., doctor, lawyer, large business
owner], trained [e.g., clerical, teacher, middle-level farmer],
skilled [e.g., small business owner, skilled manual labourer,
small farmer], semi-skilled [e.g., semi-skilled manual la-
borer, carpenter], unskilled [e.g., landless laborer, unskilled
manual laborer); and income level per month (<10,000
Indian Rupees [INR] [<16,684 Pakistani Rupees [PKR]
or < USD$165] vs. 10,000-20,000 INR [16,684-33,368 PKR
or USD$165-330] vs. >20,000 INR [>33,368 PKR
or > USD$330]).
Health-Related Factors. Prior research has documen-
ted lower body weight among current smokers than in
never or ex-smokers [24,25]; thus, we measured body
mass index (BMI; <18.0, 18-22.9, 23-24.99, > = 25) from
height and weight. The association between alcohol use
and tobacco use is also well documented [26,27]; thus,
participants were asked, “How often do you use alco-
holic beverages?” Those reporting using alcohol occa-
sionally or regularly and those who quit using alcohol
within the past six months were coded as current users
(given the low alcohol use in these countries comparedto western countries [28]); those reporting no use in the
past six months or never use were reported as nonusers.
Self-report and biological verification diabetes, hyper-
tension, and dyslipidemia were also included in the
current analyses, given the association of these factors
with smoking [3–6]. Biological sample collection in-
volved drawing 15 ml of blood (in fasting state) and col-
lecting urine (early morning void) from each participant.
The samples were transported from field sites in cold
chain to the laboratories for analysis. Sample aliquots
were also stored in cryo-vials at - 80 degrees Celsius for
future studies. The methods of analysis and external
quality control have been standardized for all biological
samples across the study sites.
Self-reported diabetes was defined as the participant
reporting having diabetes (i.e., told by physician they have
diabetes). Newly-diagnosed diabetes was defined as not
having diagnosed diabetes but having FBG ≥ 126 mg/dl or
A1c ≥ 6.5 %. Prediabetes was defined as FBG 100-125 mg/dl
or HbA1c 5.7-6.5 %. If participants self-reported diabetes
but had FBG < 126 mg/dl or A1c < 6.5 %, they still were
considered to have self-reported diabetes, as treatment
or management may have altered FBG. Self-reported
hypertension was defined as the participants reporting
having hypertension (i.e., told by physician they have
hypertension). Newly-diagnosed hypertension was defined
as not reporting hypertension but having SBP ≥ 140 or
DBP ≥ 90 mmHg. Pre-hypertension was defined as SBP
120-139 or DBP 80-89 mmHg. Self-reported dyslipidemia
was defined as the participant reporting having high lipids
(i.e., told by physician they have high lipids). Newly-
diagnosed dyslipidemia was defined as the participant
reporting not having high lipids but having TC ≥ 200 mg/dl
or LDL ≥ 130 mg/dl. If participants self-reported hy-
pertension but had SBP < 140 or DBP < 90 mmHg, they
still were considered to have self-reported hypertension,
as treatment or management may have altered these
parameters.
Tobacco exposure outcomes
Tobacco Use History. To assess tobacco use history, par-
ticipants were asked, “Have you ever used tobacco in
any form (smoking, chewing, snuff, etc.)?” and “In what
forms have you consumed tobacco: In a smoking form?
In a chewed form? In any other form (snuff, toothpaste
etc)?” Participants were also asked, “At what age did you
first start smoking regularly?” and “At what age did you first
start consuming smokeless tobacco product regularly?”
Current Tobacco Use. Participants were asked, “Within
the past 6 months, do you currently consume tobacco:
regularly (once a week); occasionally (<once a week) or
not at all?” Users were defined as those using regularly
or occasionally. Current users were asked, “How often
do you use: Smoking form? Chewed form? Any other
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(once a week); occasionally (<once a week) or not at all).
They were also asked to report on level of current and
past use of each of the following: tobacco smoking op-
tions (cigarettes; beedis; cigars; hukka/chelum/pipe); to-
bacco chewing options (pan with zarda; pan masala with
zarda; guthka); or other forms (snuff; others).
Secondhand Smoke (SHS) Exposure. Participants were
asked, “Are you exposed to tobacco smoke from others
regularly (e.g. at home, at workplace regularly, while
travelling, any other place)? How many days a week?
How much time during a day?” Those reporting at least
once a day in a week were coded as regularly exposed.
Biomarkers of Tobacco Exposure. Saliva samples were
collected from 191, 214, and 196 randomly selected par-
ticipants in Chennai, Delhi, and Karachi, respectively, to
biochemically verify self-reported tobacco use. This tool
was chosen due to greater acceptability of non-invasive,
non-stimulated salivary sampling [29] and the high sen-
sitivity of salivary cotinine in distinguishing active to-
bacco use from passive smoking with lower discrepancy
between reported and measured prevalence as compared
with urine or blood [30]. Also, Enzyme Immuno Assay
(EIA) cotinine results have shown near perfect agreement
with the reference standard GC/Mass Spectrometric con-
firmation [31]. Approximately 1000-2000 μL of saliva was
collected in salivettes manufactured by SARSTEDT AG &
Co., Germany. The samples were transported from field
sites, in Cold chain, to the laboratories for analysis. Quan-
titative estimation of cotinine was performed by Enzyme
immunoassay using kits from Salimetrics, PA 16803 USA.
Samples with higher cotinine levels were re-estimated
after further dilutions. The methods of analysis and exter-
nal quality control were standardized for all biological
samples across the study sites.
Data analysis
Stata 12.0 (College Station, Texas, USA) was used for
analysis. We used the svy technique for all analysis to ac-
count for the complex survey design [32]. Before any of
the survey estimation commands were used, the svyset
command was used to specify the variables that describe
the stratification, sampling weight, and primary sampling
unit variables. The age and sex standardized prevalence
(95 % CI) of ever and current tobacco use were calcu-
lated for the three cities using World Bank’s estimates
for regional as well as world standard population for
comparison of prevalence. Bivariate analyses were done
to examine the relationship of sociodemographic and
health-related factors to current tobacco use (outcome)
among males and females, respectively. Multivariable lo-
gistic regression analysis was then used to identify inde-
pendent correlates of tobacco use among males and
females, respectively, forcing the variables of interestinto the models. Because the relationship of age with
proportion of current tobacco use was curvilinear, we in-
cluded a quadratic term for age in multivariable analysis.
A p-value <0.05 was considered statistically significant.
Results
A total of 17,274 individuals in 10,002 households were
approached in the three study sites (7,596 participants in
Chennai, 5,420 in Delhi, 4,258 in Karachi). From these, a
total of 16,288 participants (n = 7,760 men, n = 8,527
women) were recruited (the overall response rate was
94.3 % at the participant level; Chennai 90.9 %, n = 6,906;
Delhi 98.9 %, n = 5,365; and Karachi 94.3 %, n = 4,017).
Response rate for providing blood and urine were 81.8 %
(N = 13,327/16,288) and 84.3 % (N = 13,737/16,288), re-
spectively. The number of participants with sufficient data
retained to be able to conduct the final multivariate model
was 11,260 (n = 5,062 men; n = 6,198 women).
Overall, 51.8 % of the participants were female, 61.6 %
were below the age of 45 years, 27.5 % were in the 45-60
years age group, and 10.9 % were >60 years of age.
Additional file 1: Table S1 provides comparisons of the
CARRS sample to the regional and world population in
relation to age, indicating underrepresentation among
the younger age groups in the CARRS sample. (Note:
Comparisons to the city populations also suggested simi-
lar underrepresentation of the younger age groups).
Lifetime (ever) tobacco use prevalence (standardized
for world population) was 45.0 %, 41.3 %, and 42.5 %
among males, and 7.6 %, 8.5 %, and 19.7 % among
females in Chennai, Delhi, and Karachi, respectively
(Table 1). The age and sex standardized estimates using
the regional population and world population are also
presented (Table 1). Past 6 month tobacco use pre-
valence (standardized for world population) was 38.6 %,
36.1 %, and 39.1 % among males, and 7.3 %, 7.1 %, and
18.6 % among females in Chennai, Delhi, and Karachi,
respectively (Table 2).
Average age of initiation of tobacco smoking among
lifetime smokers was 23.4 (SD = 0.7), 24.9 (SD = 0.8), and
24.5 (SD = 1.2) years in Chennai, Delhi, and Karachi, re-
spectively (not shown in Tables). Average age of initi-
ation of smokeless tobacco among lifetime users was
29.5 (SD = 0.9), 31.8 (SD = 1.2), and 27.4 (SD = 1.6) years
in Chennai, Delhi, and Karachi, respectively. Among
males, the mean age at initiation of any smoked tobacco
use was 24.9 (SD = 0.4), 25.4 (SD = 0.4), and 24.6 (SD = 0.5)
years old in Chennai, Delhi, and Karachi, respectively. The
mean age at initiation for any smokeless tobacco use
among males was 30.4 (SD = 0.8), 29.1 (SD = 0.7), and 24.9
(SD = 0.8), respectively in Chennai, Delhi, and Karachi.
Similarly for female participants, the mean age at initiation
for any smoked tobacco use was 35.0 (SD = 0.1), 28.9
(SD = 1.7), and 28.6 (SD = 1.6) and that for any smokeless
Table 1 Ever use of tobacco products in Chennai, Delhi, and Karachi
Any tobacco Tobacco smoking Chew tobacco Other tobacco
Males Females Males Females§ Males Females Males§ Females§
City % CI % CI % CI % CI % CI % CI % CI % CI
Prevalence with 95 % CI^
Chennai 45.4 [42.8,48.0] 3.4 [2.6,4.1] 33.4 [30.8,36.1] 0.1 [0.1,0.3] 16.5 [14.7,18.2] 2.0 [1.4,2.6] 1.0 [0.6,1.5] 1.4 [0.9,1.9]
Delhi 43.9 [39.1,48.7] 7.9 [5.9,9.9] 30.4 [27.1,33.7] 1.6 [0.8,2.4] 20.3 [16.4,24.2] 5.9 [4.6,7.2] 0.6 [0.3,0.8] 0.8 [0.3,1.3]
Karachi 44.7 [41.9,47.5] 13.7 [10.7,16.7] 22.6 [20.3,24.9] 1.7 [1.1,2.3] 22.9 [19.3,26.5] 11.5 [8.6,14.4] 5.4 [4.7,6.1] 0.6 [0.3,0.9]
Prevalence with 95 % CI (standardized using regional population)*
Chennai 45.3 [41.7,48.8] 7.4 [5.4,9.3] 34.7 [31.3,38.1] 0.2 [0.2,0.6] 12.8 [10.7,14.9] 4.8 [3.0,6.6] 1.6 [0.7,2.5] 2.5 [1.6,3.5]
Delhi 41.6 [36.7,46.6] 8.5 [6.1,10.9] 31.3 [27.3,35.2] 2.2 [0.9,3.5] 16.3 [13.2,19.3] 6.4 [4.6,8.3] 0.5 [0.2,0.7] 0.7 [0.3,1.0]
Karachi 43.1 [40.2,46.0] 18.7 [15.3,22.2] 25.1 [22.5,27.7] 2.2 [1.0,3.5] 18.2 [15.4,21.0] 16.0 [12.9,19.1] 5.2 [4.5,6.0] 1.0 [0.3,1.6]
Prevalence with 95 % CI (standardized using world population)†
Chennai 45.0 [41.4,48.6] 7.6 [5.5,9.7] 34.6 [31.1,38.0 0.2 [0.2,0.5] 12.6 [10.4,14.8] 5.1 [3.1,7.0] 1.7 [0.7,2.6] 2.5 [1.6,3.5]
Delhi 41.3 [36.3,46.3] 8.5 [6.0,11.0] 31.1 [27.1,35.0] 2.3 [0.9,3.7] 16.0 [13.0,19.0] 6.5 [4.5,8.4] 0.4 [0.2,0.7] 0.7 [0.3,1.1]
Karachi 42.5 [39.5,45.5] 19.7 [16.1,23.2] 25.3 [22.4,28.1] 2.3 [0.9,3.8] 17.3 [14.5,20.0] 16.9 [13.7,20.1] 5.3 [4.4,6.1] 1.0 [0.3,1.7]
^Prevalence data and 95 % confidence intervals adjusting for sampling weights
*Prevalence data and 95 % confidence intervals are age- and sex-standardized to the regional population. (Regional projected population by World Bank, 2010:
India's population for Delhi and Chennai and Pakistan's population for Karachi)
†Prevalence data and 95 % confidence intervals are age- and sex-standardized to the world’s population
§Estimates likely unreliable due to small number of subjects in this category
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(SD = 0.9) in Chennai, Delhi, and Karachi, respectively.
Data averaged across all three cities, shows that the total
mean age at initiation was lower in males than females
for both smoked and smokeless tobacco use (M= 25.0,
SD = 0.3 vs. M = 28.8, SD = 1.1, respectively for smoked
tobacco and M= 28.2, SD = 0.6 vs. M = 30.9, SD = 0.7, re-
spectively for smokeless tobacco). Among both males and
females, age of initiation of tobacco smoking versus
smokeless tobacco use was younger except in Chennai,
where the mean age of initiation of smokeless tobacco use
was lower than that for the smoked form among females
(M = 34.3, SD = 1.5 vs. M = 35, SD = 0.1, respectively).
Table 2 presents data of different types of tobacco use
among males and females. Males in Chennai most com-
monly reported use of cigarettes in Chennai (22.7 %)
and Karachi (20.8 %) and beedis (15.5 %) in Delhi. Fe-
males most commonly reported use of chewed tobacco
in Chennai (3.1 %) and Dehli (2.5 %) and pan with zarda
in Karachi (11.0 %). Table 2 also shows that mean sali-
vary cotinine values (ng/mL) were significantly higher in
current tobacco users as compared to participants who
reported no current tobacco use. Interestingly, there
were no differences in cotinine levels in relation to SHS
exposure versus no exposure among participants who
reported no tobacco use.
Bivariate correlates of male tobacco use included: age
(p < 0.001); lower education qualifications (p < 0.001);
occupation (p < 0.001); lower income (p < 0.001); lower
BMI (p < 0.001); current alcohol use (p < 0.001); and sta-
tus of diabetes (p < 0.001), hypertension (p < 0.001), anddyslipidemia (p = 0.001) (Table 3). City of residence was
not significantly associated with tobacco usage (p = 0.454).
Factors associated with tobacco use in females were simi-
lar to that in males except that tobacco use was more
prevalent in older age groups and a lack of an association
with dyslipidemia status. Also, among females, city of
residence was a significant determinant of tobacco usage
(p = 0.001), with the highest prevalence seen in Karachi.
In the multivariate logistic regression analyses (Table 4),
correlates of tobacco use among both males and females
included residing in Karachi or Delhi versus Chennai;
older age; no formal or up to primary education; earning
less income; and lower BMI. Additional correlates among
males were being a semi-skilled laborer versus not and
current alcohol use, whereas additional correlates among
females included professionals versus not working and
lower odds of having a known diagnosis of dyslipidemia.
(Note that we explored including BMI and income as con-
tinuous variables and found similar results.) Multiple im-
putation was done for missing data, and the model was
rerun, demonstrating similar results.
Discussion
We found a high prevalence of tobacco use among
males in Chennai, Delhi, and Karachi, while the pre-
valence of tobacco use among females is much lower.
Specifically, lifetime tobacco use ranged from 41.3 % in
Delhi to 45.0 % in Chennai among males and from 7.6 %
in Chennai to 19.7 % in Karachi among females. Past six
month use ranged from 36.1 % in Delhi to 39.1 % in
Karachi among males and from 7.1 % in Delhi to 18.6 %
Table 2 Past 6 month tobacco use prevalence and SHS exposure in Chennai, Delhi, and Karachi (standardized using world population)
Chennai, N = 6,906 Delhi, N = 5,364 Karachi, N = 4,017
Males Females Males Females Males Females
Variable % CI % CI % CI % CI % CI % CI
Any current tobacco use 38.6 [34.5, 42.7] 7.3 [5.3, 9.3] 36.1 [31.7, 40.5] 7.1 [5.0, 9.3] 39.1 [36.2, 42.1] 18.6 [14.8, 22.3]
Current tobacco smoking 28.9 [25.3, 32.5] 0.5 [0.0, 1.0] 27.0 [23.6, 30.4] 2.4 [1.0, 3.8] 23.8 [21.1, 26.5] 4.8 [3.0, 6.6]
Cigarettes 22.7 [19.3, 26.1] ǂ ǂ 12.2 [10.6, 13.8] ǂ ǂ 20.8 [18.3, 23.2] 1.4 [0.2, 2.6]
Beedis 8.2 [6.3, 10.0] ǂ ǂ 15.5 [12.3, 18.8] 1.8 [0.5, 3.1] 0.1 [0.1, 0.3] ǂ ǂ
Cigars 0.1 [0.0, 0.2] ǂ ǂ 0.1 [0.0, 0.2] ǂ ǂ ǂ ǂ ǂ ǂ
Hookah; Chelum; Pipe 0.1 [0.0, 0.1] ǂ ǂ 0.5 [0.1, 0.5] 0.1 [0.1, 0.2] 0.0 [0.0, 0.1] 0.1 [0.0, 0.1]
Current chewed tobacco use 13.1 [11.1, 15.0] 4.8 [3.0, 6.6] 15.3 [12.6, 17.9] 5.6 [3.8, 7.3] 19.9 [17.3, 22.6] 16.3 [13.0, 19.6]
Tobacco chew 8.3 [6.4, 10.2] 3.1 [1.9, 4.3] 9.0 [7.1, 10.9] 2.5 [1.5, 3.5] 2.7 [1.9, 3.4] 2.0 [0.5, 3.5]
Pan with zarda 0.9 [0.0, 1.8] 0.5 [0.1, 0.9] 1.4 [0.9, 1.9] 1.5 [0.5, 2.5] 7.9 [5.7, 10.0] 11.0 [8.0, 14.0]
Panmasala 0.3 [0.1, 0.6] ǂ ǂ 0.7 [0.3, 1.1] 0.6 [0.2, 0.9] 0.6 [0.2, 1.0] 1.0 [0.1, 1.9]
Gutka 1.1 [0.6, 1.5] ǂ ǂ 3.7 [2.8, 4.6] 0.6 [0.2, 1.1] 4.4 [3.1, 5.7] 1.0 [0.3, 1.7]
Current other tobacco use 4.4 [3.1, 5.7] 3.3 [2.2, 4.5] 2.2 [1.5, 2.9] 2.1 [1.2, 2.9] 10.8 [9.6, 12.0] 4.0 [2.7, 5.3]
Snuff 1.5 [0.6, 2.4] 2.2 [1.4, 3.1] 0.1 [0.0, 0.2] ǂ ǂ 5.3 [4.5, 6.0] 1.0 [0.2, 1.7]
Others 0.3 [0.0, 0.5] 0.1 [0.1, 0.2] 0.4 [0.2, 0.6] 1.1 [0.6, 1.6] 0.4 [0.1, 0.8] 0.1 [0.0, 0.1]
Regular exposure to SHS 17.7 [15.3, 20.2] 10.0 [8.2, 12.3] 14.6 [11.9, 17.3] 7.6 [5.3, 9.8] 31.3 [28.0, 34.6] 12.7 [10.1, 15.3]
Salivary Cotinine* Mean 95%CI Mean 95%CI Mean 95%CI Mean 95%CI Mean 95%CI Mean 95%CI
Current tobacco use 168.5 [92.4, 244.6] 62.0 [15.1, 108.9] 555.5 [391.0, 720.0] 306.3 [162.8, 449.9] 157.1 [118.0, 196.3] 164.0 [103.0, 225.0]
No current tobacco use 41.3 [6.8, 75.7] 26.0 [9.3, 42.8] 39.6 [15.6, 63.7] 27.0 [0.0, 57.7] 25.5 [5.2, 45.9] 18.8 [15.1, 32.5]
Nonusers with SHS 68.2 [7.3,143.7] 24.6 [3.4, 45.9] 263.4 [106.5, 420.4] 43.9 [22.6, 65.1] 104.7 [54.9, 154.4] 55.0 [20.9, 89.0]
Nonusers without SHS 58.1 [15.4, 100.8] 56.8 [9.6, 104.0] 182.6 [58.1, 307.2] 47.6 [12.1, 83.0] 76.7 [48.3, 105.2] 30.8 [12.4, 49.1]
*Using sampling weights
ǂ not reported due to insufficient data
Note: The total for Cigarettes, Beedis, Cigars, Hookah, Chelum, and Pipe may be less than Current tobacco smoking as some of the observations were missing for the type of current tobacco smoking. The total for
Tobacco chew, Pan with zarda, Panmasala, and Gutka may be less than Current chewed tobacco use as some of the observations were missing for the type of current chewed tobacco use. The total for Snuff and













Table 3 Bivariate analyses examining tobacco use among males and females in Chennai, Delhi, and Karachi
Male tobacco users Female tobacco users
Variable % 95 % CI P value % 95 % CI P value
City 0.454 0.0001
Chennai 40.9 [38.3, 43.5] 3.2 [2.6, 4.1]
Delhi 40.6 [35.9, 45.5] 7.0 [5.3, 9.1]
Karachi 42.5 [39.5, 45.5] 13.1 [10.4, 16.3]
Age group 0.0001 0.0001
20-24 29.1 [24.7, 34.0] 3.4 [2.1, 5.6]
25-34 44.1 [40.4, 47.8] 3.4 [2.2, 5.2]
35-44 46.1 [42.8, 49.5] 6.4 [4.9, 8.4]
45-54 44.2 [40.3, 48.2] 9.3 [7.5, 11.5]
55-64 36.9 [33.7, 40.2] 10.6 [8.6, 13.0]
>65 28.5 [23.2, 34.3] 13.2 [9.7, 17.7]
Education 0.0001 0.0001
Above graduation 19.8 [16.1, 24.2] 0.4 [0.0, 2.5]
Graduate 22.5 [19.4, 25.9] 1.4 [0.8, 2.7]
High school/Secondary 43.3 [40.8, 45.8] 4.0 [3.2, 5.0]
No formal education/up to primary 57.7 [54.4, 61.1] 14.9 [13.1, 16.9]
Occupation 0.0001 0.009
Not working 32.4 [28.7, 36.4] 7.0 [5.9, 8.2]
Professional 25.9 [21.3, 31.0] 5.9 [1.9, 16.9]
Trained 27.3 [24.1, 30.8] 2.0 [0.4, 9.5]
Skilled 40.8 [37.4, 44.2] 4.7 [2.6, 8.2]
Semi-skilled 51.3 [47.8, 54.7] 5.5 [3.0, 9.7]
Unskilled 56.5 [52.6, 60.3] 9.3 [6.5, 13.1]
Income 0.0001 0.0001
<10000 INR 46.4 [44.2, 48.7] 7.9 [6.7, 9.3]
10000-20000 INR 33.5 [30.1, 37.1] 5.1 [3.8, 6.8]
>20000 INR 21.8 [18.6, 25.2] 1.8 [1.1, 2.9]
BMI (Kg/m2) 0.0001 0.0001
<18.0 62.5 [56.5, 68.2] 14.3 [8.7, 22.7]
18-22.99 45.1 [41.9, 48.2] 7.1 [5.7, 8.9]
23-24.99 37.5 [33.1, 42.0] 6.8 [5.2, 8.9]
> = 25 34.6 [32.1, 37.2] 5.7 [4.7, 6.9]
Alcohol use 0.0001 0.013
Noncurrent alcohol user 31.7 [29.5, 33.9] 6.9 [5.8, 8.0]
Current alcohol user 62.4 [59.2, 65.5] 34.7 [8.3, 75.8]
Diabetes based on FPG & HbA1c values and hx of diabetes 0.0001 0.056
No/prediabetes 41.6 [39.4, 43.8] 6.0 [4.9, 7.4]
Known diabetes 33.7 [30.3, 37.3] 9.1 [6.5, 12.6]
Newly diagnosed diabetes 37.2 [33.8, 40.7] 6.5 [4.9, 8.6]
Hypertension 0.0001 0.001
No hypertension 42.5 [39.9, 45.1] 6.1 [5.0, 7.4]
Known hypertension 31.2 [27.7, 34.9] 9.4 [7.6, 11.6]
Newly diagnosed hypertension 42.9 [39.9, 45.9] 8.1 [6.5, 10.1]
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Table 3 Bivariate analyses examining tobacco use among males and females in Chennai, Delhi, and Karachi (Continued)
Dyslipidemia 0.001 0.218
No dyslipidemia 40.5 [38.4, 42.7] 6.1 [5.0, 7.5]
Known dyslipidemia 24.0 [17.8, 31.5] 5.6 [3.1, 10.0]
Newly diagnosed dyslipidemia 40.0 [37.2, 42.8] 7.3 [6.1, 8.7]
Note: P-values yielded by Pearson Chi-square test
Berg et al. BMC Public Health  (2015) 15:483 Page 8 of 12in Karachi among females. Our estimates are in line with
previous studies [10,11,33,34]. However, compared to
our estimates in Delhi and Chennai, the Global Adult
Tobacco Survey (GATS) found a higher current tobacco
use prevalence in India, specifically 34.6 % (47.9 %
among males, 20.3 % among females) [35]. Additionally,
our estimates of current tobacco use among males and
females in Karachi were lower than previously docu-
mented in Pakistan [11]. These differences in estimates
may be related to the fact that rural males (not included
in this study) have been shown to have higher tobacco
use [10,12,13] or to variation in measures used. For ex-
ample, many studies including the GATS assess current
tobacco use by asking if participants currently use to-
bacco daily, less than daily, or not at all without stating
a time frame, whereas the current study asked partici-
pants to report whether they had used these products in
the past six months, which is more specific. To put these
data in a global context, a 2012 study of 16 countries
participating in GATS [35] found that 48.6 % of men
and 11.3 % of women were tobacco users, with 40.7 % of
men and 5.0 % of women using a combustible tobacco
product [35]. As such, the tobacco use prevalence in
these three cities is lower for males than in the countries
included in the GATS but more similar to the females
included in the GATS surveys [35].
The current study also documented a wide range of
tobacco products used in this population, which is simi-
lar to findings in prior research [9]. Among males, use
of smoked tobacco was highest in Chennai and lowest in
Karachi, whereas chew tobacco rates were highest in
Karachi and lowest in Chennai. Use of smoked or chewed
tobacco among females was highest in Karachi. The most
common tobacco product used in Chennai and Karachi
was cigarettes, whereas beedis were most commonly used
in Delhi. Other common tobacco products included to-
bacco chew, particularly in Chennai and Delhi, and Pan
with Zarda, particularly in Karachi. The reasons for the
differences in tobacco products used in these cities need
to be explored.
In multivariable regression, factors associated with to-
bacco use among each males and females included resi-
ding in Karachi or Delhi versus Chennai. The reasons
for these city differences are unclear; however, these
findings may be partially attributed to lower price of to-
bacco products in Pakistan in comparison with India[36]. An additional finding indicated that, while Karachi
had the highest tobacco use prevalence among the three
cities for both men and women, lifetime tobacco use
among males across the three cities were quite similar,
which may suggest lower tobacco prices in Pakistan en-
couraging experimentation with tobacco. In addition,
older age, lower education, earning less income, and
lower BMI were correlates of tobacco use among both
males and females, which aligns with prior research
[10,12,13]. Another correlate of tobacco use among males
was alcohol use. This is in line with well-established re-
search in other countries documenting the connection
between other substance use, particularly alcohol use, and
smoking, both in this region and outside this region
[10,12,13,37,38]. For females, another correlate of tobacco
use was lower odds of having newly diagnosed dyslipi-
demia, which has not been documented previously.
The sociodemographic factors associated with tobacco
use among the genders reflected one very important dif-
ference – males who were semi-skilled laborers versus
not working were at greater risk for being a tobacco
user, whereas females who were professionals versus not
working were at greater risk for use. This may reflect the
global trend of the tobacco industry targeting females in
developing countries to increase their total market, par-
ticularly by targeting females who are educated and in
urban settings [39–41].
An important strength of the current study was vali-
dation of self-reported tobacco use by estimating salivary
cotinine level in a random subsample. As expected, the
mean cotinine levels were higher among current tobacco
users compared to nonusers. However, average cotinine
levels were higher among both users and nonusers than
shown in prior research [42,43]. For example, a 2000
study of 222 tobacco users and 97 nonusers found that
mean salivary cotinine was 166 ng/ml in tobacco users
and 6.3 ng/ml in nonusers. This study indicated an
optimal cut-off to discriminate users from nonusers is
between 7 and 13 ng/ml. The nonusers in the CARRS
sample had higher cotinine levels than this cut-off point
(range 18.8 to 41.6). This prior study indicated that
smoking status of significant others was associated with
higher cotinine levels among nonusers [42]; perhaps the
high prevalence of tobacco use in these three cities im-
plies high levels of SHS exposure impacting the cotinine
levels of nonusers. However, another interesting finding
Table 4 Multivariate regression predicting tobacco use among males and females in Chennai, Delhi, and Karachi
Males Females




Delhi 1.66 [1.31,2.10] 0.0001 2.85 [1.91,4.26] 0.0001
Karachi 2.11 [1.71,2.59] 0.0001 4.33 [3.01,6.24] 0.0001
Age (centered at mean) 1.01 [1.00,1.02] 0.030 1.05 [1.03,1.06] 0.0001
Age squared 0.99 [1.00,1.00] 0.0001 0.99 [1.00,1.00] 0.055
Education
Above graduation® Ref Ref
Graduate 1.03 [0.70,1.51] 0.873 2.80 [0.30,26.24] 0.364
High/Secondary 1.51 [1.04,2.19] 0.031 8.47 [1.03,69.46] 0.047
No formal education/up to primary 2.67 [1.72,4.15] 0.0001 20.97 [2.53,173.62] 0.005
Occupation
Not working® Ref Ref
Professional 1.01 [0.65,1.57] 0.961 3.58 [1.12,11.40] 0.031
Trained 0.83 [0.58,1.17] 0.279 0.71 [0.19,2.64] 0.603
Skilled 1.06 [0.80,1.41] 0.671 0.93 [0.38,2.24] 0.870
Semi-skilled 1.36 [1.05,1.77] 0.020 0.56 [0.25,1.24] 0.151
Unskilled 1.23 [0.91,1.65] 0.173 1.52 [0.93,2.49] 0.095
Income
<10000 INR® Ref Ref
10000-20000 INR 0.81 [0.65,1.00] 0.052 0.68 [0.46,1.00] 0.051
>20000 INR 0.49 [0.36,0.65] 0.0001 0.37 [0.19,0.71] 0.003
BMI
<18.0 ® Ref Ref
18-22.99 0.50 [0.38,0.67] 0.0001 0.48 [0.27,0.85] 0.013
23-24.99 0.37 [0.26,0.52] 0.0001 0.41 [0.22,0.77] 0.006
> = 25 0.35 [0.26,0.46] 0.0001 0.40 [0.22,0.71] 0.002
Alcohol use
No® Ref Ref
Yes 4.17 [3.52,4.94] 0.060 8.18 [0.91,73.55] 0.911
Diabetes based on FPG & HbA1c values and hx of diabetes
No diabetes® Ref Ref
Known diagnosis diabetes 1.02 [0.80,1.29] 0.904 1.40 [0.89,2.20] 0.140
Newly diagnosed diabetes 1.02 [0.83,1.24] 0.878 0.97 [0.63,1.50] 0.883
Hypertension
Normotension® Ref Ref
Known diagnosis hypertension 0.87 [0.69,1.09] 0.208 0.91 [0.65,1.28] 0.580
Newly diagnosed hypertension 0.90 [0.76,1.06] 0.204 0.89 [0.67,1.19] 0.435
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Table 4 Multivariate regression predicting tobacco use among males and females in Chennai, Delhi, and Karachi (Continued)
Dyslipidemia
No dyslipidemia® Ref Ref
Known diagnosis dyslipidemia 0.71 [0.41,1.22] 0.212 0.39 [0.16,0.93] 0.034
Newly diagnosed dyslipidemia 1.09 [0.94,1.27] 0.227 1.09 [0.83,1.44] 0.518
Adjusted Wald test for all parameters F(24,69) = 24.10, p < 0.0001 F(24,68) = 10.71, p < 0.0001
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between nonusers exposed to SHS versus not exposed,
which warrants further examination.
The current study has important implications for re-
search and practice. In terms of research, this study sug-
gests the need for more longitudinal research regarding
correlates of tobacco use among individuals in India and
Pakistan, given the relatively limited scope of factors in-
cluded in this data set. There is specific interest in the
relationship between tobacco use and comorbid condi-
tions like hypertension, diabetes, and dyslipidemia which
cannot be adequately explored in a cross-sectional ana-
lysis like ours. We will have the opportunity to explore
this as our cohort study matures. In addition, the social
norms, tobacco control policies, and potential exposure
to tobacco marketing should be examined in these dif-
fering contexts to determine the impact of these socio-
contextual factors that impact tobacco use initiation and
maintenance among males and females. Regarding prac-
tice, policies involved in the Framework Convention on
Tobacco Control, particularly those impacting the social
norms of tobacco use (e.g., public smoke-free policies,
regulation of tobacco advertising) and systems to aid in
cessation, must be supported in order to influence to-
bacco use initiation and maintenance among this popu-
lation. In terms of practice implications, it appears from
our analysis that people with known risks for heart
disease and stroke (e.g., diabetes, hypertension) are less
likely to smoke. Again, more longitudinal exploration of
these relationships will be helpful, but regardless, practi-
tioners must continue to address tobacco use in the cli-
nical setting, particularly among patients with medical
comorbidities.
Limitations
A limitation of the CARRS model is that the study setting
is urban and does not include the larger rural population;
this sample also is limited due to an underrepresentation
of the younger age groups [20,44]. Second, because of the
cross-sectional nature of this study, we cannot determine
the directionality of the relationships documented. How-
ever, the longitudinal nature of the CARRS study will
allow us to address this limitation in future research.
Moreover, the multivariate model allows us to determine
the amount of variance in tobacco use accounted for by
the other factors assessed in this study. Another limitationis that, because the primary aim of this study was not to
explore all dimensions of tobacco use, several important
factors potentially related to tobacco use (e.g., social
norms, exposure to marketing) were not assessed. Ad-
ditionally, our time-frame for tobacco use (i.e., past
6 month use) is somewhat unconventional but was used
to capture the relatively low overall use of tobacco pro-
ducts among women in this region. This has implications
for comparability to findings from other studies using
other assessment approaches and other time frames. Fi-
nally, due to the multiple tobacco products assessed and
the variability in number of products used, frequency of
use, and variability in nicotine content across tobacco
products, our current analysis of cotinine levels was
mainly aimed at examining cotinine levels among current
tobacco users versus nonusers, which confirmed diffe-
rences between users and nonusers.
Conclusions
Tobacco use prevalence is high, particularly among men,
in Chennai, Delhi, and Karachi. Moreover, there is a
broad range of tobacco products being used and diffe-
rences in use prevalence of these products within these
specific cities. Thus, tobacco control policy implementa-
tion is critical to address tobacco-related morbidity and
mortality. Future research should examine psychosocial
and contextual factors influencing tobacco use among
those living in India and Pakistan. Specifically, factors
impacting differential prevalence of tobacco use among
males and females, the social norms of tobacco and
other substance use, and the impact of health problems
on cessation should be examined further. In addition, in-
terventions and policies that might impact attitudes to-
ward tobacco and social norms regarding tobacco use
should be investigated and considered.
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